Shift from the current target‑to‑disease paradigm
We care deeply about the future of pain research and are committed to creating real change for people suffering from chronic pain.
Our vision is to create the most innovative research pipeline for pain through patient-inspired R&D.
At Grünenthal, we aspire to establish clear, novel project starting points with confirmed disease-to-target links in the short- to mid-term (2020–2030).
We look forward to embracing the next era of pain treatment, through collaboration, to find solutions for pain.
We want to re-define the field of pain, creating specialised treatments through patient-inspired R&D.
We understand pain is not just a symptom but also an entire condition in itself that requires specialised treatment.
We have invested heavily in R&D to produce an extensive portfolio of pain treatments.